Merkies ISJ, et al. - Given that intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP), researchers studied the effectiveness and safety of the IVIG IgPro10 (Privigen®) for treatment of CIDP. For this investigation, results from PRIMA, a prospective, open-label, single-arm study of IVIG in Ig-naïve or IVIG-pretreated subjects and PATH, a double-blind, randomized study including an open-label, single-arm IVIG phase in IVIG-pretreated subjects were examined separately and together. Data reported that adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) response rate was 60.7% in all PRIMA subjects at Week 25 and 72.9% in PATH. There were no clear demographic differences between early and late responders. This investigation confirmed the effectiveness and safety of IgPro10, a recently FDA-approved IVIG for CIDP, in a population of pre-treated CIDP subjects.